KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBIT (2017 - 2025)

Aquestive Therapeutics has reported EBIT over the past 9 years, most recently at -$28.8 million for Q4 2025.

  • Quarterly results put EBIT at -$28.8 million for Q4 2025, down 112.38% from a year ago — trailing twelve months through Dec 2025 was -$71.1 million (down 130.9% YoY), and the annual figure for FY2025 was -$71.1 million, down 130.9%.
  • EBIT for Q4 2025 was -$28.8 million at Aquestive Therapeutics, down from -$11.5 million in the prior quarter.
  • Over the last five years, EBIT for AQST hit a ceiling of $55000.0 in Q2 2024 and a floor of -$28.8 million in Q4 2025.
  • Median EBIT over the past 5 years was -$8.9 million (2022), compared with a mean of -$9.7 million.
  • Biggest five-year swings in EBIT: surged 101.31% in 2024 and later tumbled 20769.09% in 2025.
  • Aquestive Therapeutics' EBIT stood at -$11.7 million in 2021, then grew by 8.19% to -$10.7 million in 2022, then skyrocketed by 63.49% to -$3.9 million in 2023, then tumbled by 247.2% to -$13.6 million in 2024, then crashed by 112.38% to -$28.8 million in 2025.
  • The last three reported values for EBIT were -$28.8 million (Q4 2025), -$11.5 million (Q3 2025), and -$11.4 million (Q2 2025) per Business Quant data.